From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting

Steven Rowe, Brandon Luber, Monique Makell, Patricia Brothers, Jo Ann Santmyer, Megan D. Schollenberger, Hannah Quinn, Daniel L. Edelstein, Frederick S. Jones, Karen Bleich, William Sharfman, Evan Lipson

Research output: Contribution to journalArticle

Abstract

Melanoma currently lacks a reliable blood-based biomarker of disease activity, although circulating tumor DNA (ctDNA) may fill this role. We investigated the clinical utility (i.e., impact on clinical outcomes and interpretation of radiographic data) of measuring ctDNA in patients with metastatic or high-risk resected melanoma. Patients were prospectively accrued into ≥ 1 of three cohorts, as follows. Cohort A: patients with radiographically measurable metastatic melanoma who underwent comparison of ctDNA measured by a BEAMing digital PCR assay to tissue mutational status and total tumor burden; when appropriate, determinations about initiation of targeted therapy were based on ctDNA data. Cohorts B and C: patients with BRAF- or NRAS-mutant melanoma who had either undergone surgical resection of high-risk disease (cohort B) or were receiving or had received medical therapy for advanced disease (cohort C). Patients were followed longitudinally with serial ctDNA measurements with contemporaneous radiographic imaging to ascertain times to detection of disease activity and progressive disease, respectively. The sensitivity and specificity of the ctDNA assay were 86.8% and 100%, respectively. Higher tumor burden and visceral metastases were found to be associated with detectable ctDNA. In two patients in cohort A, ctDNA test results revealed a targetable mutation where tumor testing had not; both patients experienced a partial response to targeted therapy. In four of 30 patients with advanced melanoma, ctDNA assessments indicated evidence of melanoma activity that predicted radiographic evidence of disease progression by 8, 14, 25, and 38 weeks, respectively. CtDNA was detectable in three of these four patients coincident with radiographic evaluations that alone were interpreted as showing no evidence of neoplastic disease. Our findings provide evidence for the clinical utility of integrating ctDNA data in managing patients with melanoma in a real-world setting.

Original languageEnglish (US)
JournalMolecular Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Melanoma
DNA
Neoplasms
Tumor Burden
Disease Progression
Therapeutics
Biomarkers
Neoplasm Metastasis
Sensitivity and Specificity
Polymerase Chain Reaction
Mutation

Keywords

  • circulating tumor DNA
  • ctDNA
  • melanoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cancer Research

Cite this

From validity to clinical utility : the influence of circulating tumor DNA on melanoma patient management in a real-world setting. / Rowe, Steven; Luber, Brandon; Makell, Monique; Brothers, Patricia; Santmyer, Jo Ann; Schollenberger, Megan D.; Quinn, Hannah; Edelstein, Daniel L.; Jones, Frederick S.; Bleich, Karen; Sharfman, William; Lipson, Evan.

In: Molecular Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Rowe, Steven ; Luber, Brandon ; Makell, Monique ; Brothers, Patricia ; Santmyer, Jo Ann ; Schollenberger, Megan D. ; Quinn, Hannah ; Edelstein, Daniel L. ; Jones, Frederick S. ; Bleich, Karen ; Sharfman, William ; Lipson, Evan. / From validity to clinical utility : the influence of circulating tumor DNA on melanoma patient management in a real-world setting. In: Molecular Oncology. 2018.
@article{6024352079fb4ec9b6f108eeb85c6552,
title = "From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting",
abstract = "Melanoma currently lacks a reliable blood-based biomarker of disease activity, although circulating tumor DNA (ctDNA) may fill this role. We investigated the clinical utility (i.e., impact on clinical outcomes and interpretation of radiographic data) of measuring ctDNA in patients with metastatic or high-risk resected melanoma. Patients were prospectively accrued into ≥ 1 of three cohorts, as follows. Cohort A: patients with radiographically measurable metastatic melanoma who underwent comparison of ctDNA measured by a BEAMing digital PCR assay to tissue mutational status and total tumor burden; when appropriate, determinations about initiation of targeted therapy were based on ctDNA data. Cohorts B and C: patients with BRAF- or NRAS-mutant melanoma who had either undergone surgical resection of high-risk disease (cohort B) or were receiving or had received medical therapy for advanced disease (cohort C). Patients were followed longitudinally with serial ctDNA measurements with contemporaneous radiographic imaging to ascertain times to detection of disease activity and progressive disease, respectively. The sensitivity and specificity of the ctDNA assay were 86.8{\%} and 100{\%}, respectively. Higher tumor burden and visceral metastases were found to be associated with detectable ctDNA. In two patients in cohort A, ctDNA test results revealed a targetable mutation where tumor testing had not; both patients experienced a partial response to targeted therapy. In four of 30 patients with advanced melanoma, ctDNA assessments indicated evidence of melanoma activity that predicted radiographic evidence of disease progression by 8, 14, 25, and 38 weeks, respectively. CtDNA was detectable in three of these four patients coincident with radiographic evaluations that alone were interpreted as showing no evidence of neoplastic disease. Our findings provide evidence for the clinical utility of integrating ctDNA data in managing patients with melanoma in a real-world setting.",
keywords = "circulating tumor DNA, ctDNA, melanoma",
author = "Steven Rowe and Brandon Luber and Monique Makell and Patricia Brothers and Santmyer, {Jo Ann} and Schollenberger, {Megan D.} and Hannah Quinn and Edelstein, {Daniel L.} and Jones, {Frederick S.} and Karen Bleich and William Sharfman and Evan Lipson",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/1878-0261.12373",
language = "English (US)",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",

}

TY - JOUR

T1 - From validity to clinical utility

T2 - the influence of circulating tumor DNA on melanoma patient management in a real-world setting

AU - Rowe, Steven

AU - Luber, Brandon

AU - Makell, Monique

AU - Brothers, Patricia

AU - Santmyer, Jo Ann

AU - Schollenberger, Megan D.

AU - Quinn, Hannah

AU - Edelstein, Daniel L.

AU - Jones, Frederick S.

AU - Bleich, Karen

AU - Sharfman, William

AU - Lipson, Evan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Melanoma currently lacks a reliable blood-based biomarker of disease activity, although circulating tumor DNA (ctDNA) may fill this role. We investigated the clinical utility (i.e., impact on clinical outcomes and interpretation of radiographic data) of measuring ctDNA in patients with metastatic or high-risk resected melanoma. Patients were prospectively accrued into ≥ 1 of three cohorts, as follows. Cohort A: patients with radiographically measurable metastatic melanoma who underwent comparison of ctDNA measured by a BEAMing digital PCR assay to tissue mutational status and total tumor burden; when appropriate, determinations about initiation of targeted therapy were based on ctDNA data. Cohorts B and C: patients with BRAF- or NRAS-mutant melanoma who had either undergone surgical resection of high-risk disease (cohort B) or were receiving or had received medical therapy for advanced disease (cohort C). Patients were followed longitudinally with serial ctDNA measurements with contemporaneous radiographic imaging to ascertain times to detection of disease activity and progressive disease, respectively. The sensitivity and specificity of the ctDNA assay were 86.8% and 100%, respectively. Higher tumor burden and visceral metastases were found to be associated with detectable ctDNA. In two patients in cohort A, ctDNA test results revealed a targetable mutation where tumor testing had not; both patients experienced a partial response to targeted therapy. In four of 30 patients with advanced melanoma, ctDNA assessments indicated evidence of melanoma activity that predicted radiographic evidence of disease progression by 8, 14, 25, and 38 weeks, respectively. CtDNA was detectable in three of these four patients coincident with radiographic evaluations that alone were interpreted as showing no evidence of neoplastic disease. Our findings provide evidence for the clinical utility of integrating ctDNA data in managing patients with melanoma in a real-world setting.

AB - Melanoma currently lacks a reliable blood-based biomarker of disease activity, although circulating tumor DNA (ctDNA) may fill this role. We investigated the clinical utility (i.e., impact on clinical outcomes and interpretation of radiographic data) of measuring ctDNA in patients with metastatic or high-risk resected melanoma. Patients were prospectively accrued into ≥ 1 of three cohorts, as follows. Cohort A: patients with radiographically measurable metastatic melanoma who underwent comparison of ctDNA measured by a BEAMing digital PCR assay to tissue mutational status and total tumor burden; when appropriate, determinations about initiation of targeted therapy were based on ctDNA data. Cohorts B and C: patients with BRAF- or NRAS-mutant melanoma who had either undergone surgical resection of high-risk disease (cohort B) or were receiving or had received medical therapy for advanced disease (cohort C). Patients were followed longitudinally with serial ctDNA measurements with contemporaneous radiographic imaging to ascertain times to detection of disease activity and progressive disease, respectively. The sensitivity and specificity of the ctDNA assay were 86.8% and 100%, respectively. Higher tumor burden and visceral metastases were found to be associated with detectable ctDNA. In two patients in cohort A, ctDNA test results revealed a targetable mutation where tumor testing had not; both patients experienced a partial response to targeted therapy. In four of 30 patients with advanced melanoma, ctDNA assessments indicated evidence of melanoma activity that predicted radiographic evidence of disease progression by 8, 14, 25, and 38 weeks, respectively. CtDNA was detectable in three of these four patients coincident with radiographic evaluations that alone were interpreted as showing no evidence of neoplastic disease. Our findings provide evidence for the clinical utility of integrating ctDNA data in managing patients with melanoma in a real-world setting.

KW - circulating tumor DNA

KW - ctDNA

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=85052968940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052968940&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12373

DO - 10.1002/1878-0261.12373

M3 - Article

C2 - 30113761

AN - SCOPUS:85052968940

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

ER -